Agenda for Day Two - Tuesday, March 23, 2027Tuesday, 23 March 2027 - ET (Eastern Time, GMT-05:00)

• Master revenue recognition frameworks applicable across company stages, from first-product launches to complex multi-product portfolios, including advanced GTN methodologies, variable consideration assessments, and technical documentation requirements
• Work through increasingly complex collaboration agreements, licensing arrangements, and multi-element contracts using interactive exercises covering performance obligations, milestone accounting, and transaction price allocation challenges faced by both emerging and established companies
• Learn from detailed case studies spanning pre-launch accounting challenges, government pricing complexities, portfolio-level consolidation considerations, and cross-border IFRS and US GAAP alignment issues, with practical frameworks and technical memo guidance
• Participate in interactive polling and peer discussions to benchmark your revenue recognition challenges and identify tactical solutions from companies at similar stages

• Navigate accounting treatment for rapidly evolving US healthcare reform including MFN pricing models, ACA modifications, and Medicaid/Medicare changes, with practical guidance on managing net price volatility and emerging disclosure requirements
• Master emerging rebate program accounting including Project Beacon's 340B rebate model for MFP drugs, covering calculation methodologies, reserve integration, and financial statement presentation
• Address IRA implementation challenges including Medicare Drug Price Negotiation Program impacts, strategic portfolio decisions, and financial reporting requirements for investor communications

• Master California's climate disclosure requirements (SB 253 and SB 261), including how they impact US-domiciled life sciences companies with California operations, and develop audit programs for Scope 1, 2, and 3 emissions reporting and verification processes
• Navigate European ESG regulations, including the Corporate Sustainability Reporting Directive (CSRD), and learn strategies for integrating ESG metrics into financial reporting while managing country-level implementation requirements
• Build audit readiness and assurance frameworks to meet expanding ESG compliance demands, including practical guidance on data collection, internal controls, documentation, and preparing for external auditor scrutiny

• Master accounting for M&A, strategic partnerships, licensing arrangements, and innovative financing structures emerging in today's market
• Navigate key judgment areas, including investment classification, consolidation vs equity method decisions, and purchase price allocation for life sciences assets
• Explore real-world considerations around milestone payments, contingent consideration, R&D funding arrangements, and multi-element transactions
• Understand how anti-trust scrutiny, geopolitical factors, and funding constraints are driving new deal structures and related accounting complexities

• Benchmark guardrails, approval processes, and decision-making frameworks for AI adoption, including the role of boards of directors and audit committees in AI governance and oversight
• Develop board and audit committee communication strategies that demonstrate AI value, including who should present initiatives (legal, controllership, IT, or other functions) and how to frame cost savings, efficiency gains, and productivity improvements across short-term and long-term contexts
• Implement oversight controls, quality assurance mechanisms for financial reporting, tool selection criteria, and best practices for managing organizational adoption and change across finance teams

• Transform ERP implementation from technical upgrade to strategic business enabler that drives operational efficiency and supports cost-cutting initiatives
• Discuss real-world response strategies for system downtime, cyber attacks, and data loss incidents that impact financial close and audit timelines
• Navigate standardized enterprise systems while maintaining subsidiary autonomy across multi-entity structures and different maturity levels

This exclusive, industry-only session creates a protected environment where financial leaders from small and emerging biotech companies can engage in candid, unfiltered discussions about their unique challenges and opportunities. Limited strictly to biotech company participants, this forum fosters authentic peer-to-peer exchange and collaborative problem-solving in a non-competitive atmosphere.

As smaller biotech organizations navigate complex financial landscapes with limited resources, this session provides a rare opportunity to share experiences, discuss sensitive topics, and develop practical solutions alongside peers who truly understand your specific constraints and pressures.

CPE Credits Available 1.0

• Explore how evolving technology and automation are fundamentally reshaping the skills, competencies, and career paths required for finance and accounting professionals in life sciences
• Discuss practical strategies for upskilling existing teams to work effectively with new tools and technologies while maintaining critical thinking and judgment capabilities

This open forum allows for senior-level executives to exchange ideas and best practices for driving internal and organizational success through efficiencies, technology, and new innovations.

*Informa reserves the right to qualify participants for this Summit. Attendees must be Director/Head of/VP/C-Suite with 10+ years’ experience and currently employed by a life sciences manufacturer.